FBXO11

Across TCGA pan-cancer cohorts, FBXO11 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FBXO11 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher FBXO11 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FBXO11 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

ACC, LUAD, and THCA are the cancer types where FBXO11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.010	0.667	<.001	45	view →
LUAD	OS	Median	All	0.307	0.834	.001	24	view →
THCA	DFS	Median	All	0.161	0.829	.009	9	view →
GBM	OS	Median	All	0.062	0.416	.001	6	view →
SKCM	DFS	Median	II,III,IV	1.000	0.561	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FBXO11–ACC (DFS)

Open the ACC breakdown →